There is no FDA-approved generic version of brand-name weight loss drugs since pharmaceutical companies still hold patents on ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Harvest Portfolios Group Inc. ("Harvest") is pleased to announce that it has paid over C$1 billion in total ETF cash distributions since inception. Harvest ETFs is one of Canada's largest providers of ...

Oral Solid Dosage Pharmaceutical Formulation Market is projected to achieve US$ 8,95,636.0 million by 2034 at a CAGR of 3.7%.

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...